Why FIH oncology trials fail before they start
A perspective on site mix, protocol assumptions, activation delays, and hidden execution risk.
Insights
Signals worth reviewing before early oncology execution.
A practical resource page for public research, oncology conference signals, and our perspective on FIH execution risk. Public Apex AI articles and official sources such as ASCO, ESMO, AACR, and SITC are available as filterable source material with original links preserved.
Featured perspectives
Start with the questions sponsors usually discover too late.
These short editorial themes give the Insights page a stable point of view even when external public-source feeds are temporarily unavailable.
Site-level activation risk vs traditional feasibility
Why averages and prestige-based KOL selection can miss the operational tails that matter.
China innovation drugs going global
How global development strategy, region selection, and trial design affect credibility outside China.
How oncology site selection should differ by mechanism
Why ADCs, bispecifics, KRAS, CAR-T, radioligands, DDR assets, and TKIs should not use the same site logic.
Article library
Public research and oncology conference signals
A unified library of public Apex AI articles and official oncology meeting sources such as ASCO, ESMO, AACR, and SITC. Filter by source, topic, or keyword; cards preserve public metadata and official source links only.
Partial sync: ASCO Publications, SITC News Releases, SITC Annual Meeting temporarily unavailable.
Source: All sources · Topic: All topics · 25 articles · 10 per page
Call for Submissions: 2027 AACR June L. Biedler Prize for Cancer Journalism
The AACR is inviting journalists to submit their stories for the 2027 AACR June L. Biedler Prize for Cancer Journalism. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official source
AACR Applauds Bipartisan Senate Provision to Delay Harmful OMB Grantmaking Rule
PHILADELPHIA – The American Association for Cancer Research (AACR) commends Senate appropriators for including a bipartisan provision in its version of the fiscal year (FY) 2027 continuing resolution (CR) that... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official sourceAACR Center for Cancer Clinical Trials Announces First Patient Enrolled in Phase II Clinical Trial for Locally Advanced Gastroeso...
PHILADELPHIA – The AACR Center for Cancer Clinical Trials, led by the American Association for Cancer Research (AACR), today announced that the AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastro... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official source
A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses
After a median follow-up of 16.5 months, none of the participants developed pancreatic cancer, and some of the precancerous lesions shrank or stopped growing. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official sourceMen May Be More Likely Than Women to Receive Later-stage Diagnoses for Many Cancer Types in the United States
Researchers say the study’s findings, published in Cancer Epidemiology, Biomarkers & Prevention, could provide insight into the discrepancies in cancer outcomes between men and women. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official source
AACR Statement and Call to Action Concerning OMB Proposal to Rewrite the Rules for Scientists and Physicians Who Are Improving Pu...
The American Association for Cancer Research (AACR) is deeply concerned that the recent action of the White House Office of Management and Budget (OMB) to propose a new set of regulations on how federal grants... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official sourceAACR Names Matthew Vander Heiden, MD, PhD, FAACR, as Editor-in-Chief of the Journal Cancer Discovery
The American Association for Cancer Research (AACR) has appointed Matthew Vander Heiden, MD, PhD, FAACR, as editor-in-chief of Cancer Discovery. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official sourceAACR Releases Cancer Disparities Progress Report 2026
The report features latest statistics, including promising signs of progress, and 10 compelling personal stories. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official sourceAI at ASCO 2026: From Topic to Tool
AI tags 220 abstracts, the largest subtrack at ASCO 2026. Most of it is applied to concrete tasks; trial matching is where it meets drug development most directly.
Open AAI articleGenitourinary Cancer at ASCO 2026 — Prostate, Bladder, Kidney
Prostate, bladder, and kidney cancer studies from ASCO 2026, organized by cancer, with trial sizes, hazard ratios, response rates, and data tables.
Open AAI article